Who Paid My Doc
Jeffrey Mangel
Obstetrics & Gynecology Cleveland, OH Medical Doctor
NPI 1679689913 CMS profile 166597
2500 Metrohealth Dr, Mhmc-Ob/Gyn, Cleveland, OH 44109
General payments
$60,562
Research payments
$136,900
Ownership & investment interest
$0
Research they led as principal investigator
$825,916
Through program year 2025, Jeffrey Mangel of Cleveland, OH is reported in the CMS Open Payments database as having received $60,562 across 178 general payments and $136,900 in research payments paid to them. Separately, studies naming them as principal investigator received $825,916 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $23,817 | 36 | |
| 2024 | General | $3,008 | 21 | |
| 2023 | General | $2,869 | 18 | |
| 2022 | General | $11,648 | 37 | |
| 2022 | Research | $53,150 | 5 | |
| 2021 | General | $1,893 | 28 | |
| 2021 | Research | $2,620 | 4 | |
| 2020 | General | $2,210 | 14 | |
| 2020 | Research | $19,376 | 9 | |
| 2019 | General | $15,116 | 24 | |
| 2019 | Research | $61,753 | 21 |
Beside peers
- Jeffrey Mangel
- Obstetrics & Gynecology median
- Middle half of Obstetrics & Gynecology
- National median
In program year 2025, general payments to Jeffrey Mangel were reported at $23,817. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.
Show as a table
| Year | Jeffrey Mangel | Obstetrics & Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $15,116 | $172 | $62–$391 | $163 |
| 2020 | $2,210 | $94 | $36–$222 | $114 |
| 2021 | $1,893 | $136 | $42–$369 | $132 |
| 2022 | $11,648 | $160 | $50–$433 | $149 |
| 2023 | $2,869 | $169 | $56–$423 | $160 |
| 2024 | $3,008 | $152 | $50–$371 | $164 |
| 2025 | $23,817 | $158 | $51–$401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
567
Drug cost
$225,833
Branded share of claims
74.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 155 | $136,392 | |
| Gemtesa Vibegron | Brand | 54 | $54,191 | |
| Mirabegron Er Mirabegron | Brand | 21 | $13,774 | |
| Premarin Estrogens, Conjugated | Brand | 25 | $10,475 | |
| Estradiol | Generic | 68 | $3,831 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 84 | $2,583 | |
| Trospium Chloride | Generic | 23 | $2,348 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 63 | $1,146 | |
| Solifenacin Succinate | Generic | 11 | $604 | |
| Tamsulosin Hcl | Generic | 15 | $188 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 32 billing codesPaid by Medicare
$40,507
Medicare patients
120
Services billed
572
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 71% | |
| Arthritis | 66% | |
| Diabetes | 30% | |
| Depression | 28% | |
| Osteoporosis | 27% | |
| Ischemic heart disease | 22% | |
| Chronic kidney disease | 20% | |
| COPD | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
217 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obstetrics & Gynecology in Ohio
Samir Ahuja
Obstetrics & Gynecology · Mentor, OH
Burton Brodsky
Obstetrics & Gynecology · Sylvania, OH
Sandor Mecs
Obstetrics & Gynecology · Steubenville, OH
David Schwartz
Obstetrics & Gynecology · Cincinnati, OH
Erin Olah
Obstetrics & Gynecology · Columbus, OH
David Portman
Obstetrics & Gynecology · Columbus, OH
Related records
Obstetrics & Gynecology in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Obstetrics & Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.